Lenacapavir HIV Shot: Where the Rollout Stands in 2026
- 10 views
- 0 likes
- 0 comments
- All languages combined

Sign in and earn +30 points by reading this
Read to the end, wait a few seconds, then tap the claim button below.
In short
As of 13 November 2026, lenacapavir, the twice-yearly HIV prevention injection, is being rolled out in Africa and beyond: UNAIDS says 24 countries are expected to have started programme delivery by the end of 2026 [1]. A first generic, to cost US$40 a year in 120 countries, was announced on 2 November with tentative FDA approval [3][4].
Key takeaways
- Lenacapavir (LEN) for PrEP is a twice-yearly injection with a mandatory oral loading dose, recommended by WHO since July 2025 [1][6].
- The US FDA approved Gilead's brand, Yeztugo, on 18 June 2025 for adults and adolescents weighing at least 35 kg [5].
- UNAIDS published an implementation guide on 11 November 2026; Eswatini and Zambia began programme delivery in December 2025 [1].
- Unitaid said on 2 November 2026 that more than 125,000 people in 10 early-adopter African countries had started lenacapavir [3].
- On 2 November 2026 Dr. Reddy's announced FDA tentative approval for its generic, to be sold at US$40 per person per year in 120 countries [3][4].
- AVAC, an HIV prevention advocacy group, reports that demand is outpacing supply and that some countries are slowing promotion until more doses arrive [2].
- Decisions about PrEP belong with a health worker, and HIV testing is required before each injection [5].
On this page 11 sections
- What is the lenacapavir HIV shot?
- How effective is lenacapavir for HIV prevention?
- Which countries have lenacapavir for PrEP?
- How much does lenacapavir cost?
- Is generic lenacapavir approved?
- What are the problems with the lenacapavir rollout?
- What happens next with lenacapavir?
- Common mistakes
- Frequently asked questions
- Glossary
- Sources
What is the lenacapavir HIV shot?
Lenacapavir is a long-acting HIV medicine that, given as an injection twice a year, is used as pre-exposure prophylaxis (PrEP), meaning medicine taken by HIV-negative people to prevent infection [1][5]. UNAIDS describes it as a safe, acceptable and highly efficacious twice-yearly injectable PrEP option, given with a mandatory oral loading dose at the start [1].
It works differently from older HIV drugs. Gilead, the developer, calls it a capsid inhibitor: it targets the protein shell (capsid) of HIV and is designed to block the virus at several stages of its life cycle [5]. Gilead sells it in the United States under the brand name Yeztugo [5].
WHO recommended injectable lenacapavir as an additional PrEP option on 14 July 2025, alongside daily oral PrEP, injectable cabotegravir and the dapivirine vaginal ring [6]. WHO Director-General Tedros Adhanom Ghebreyesus called it "the next best thing" to an HIV vaccine [6].
How effective is lenacapavir for HIV prevention?
In Gilead's two Phase 3 trials, at least 99.9% of participants who received lenacapavir remained HIV-negative [5].
- PURPOSE 1, in cisgender women in sub-Saharan Africa: zero HIV infections among 2,134 participants in the lenacapavir group at the primary analysis, superior to daily oral Truvada [5].
- PURPOSE 2, among cisgender men and gender-diverse people in geographically diverse settings: two infections among 2,179 participants in the lenacapavir group [5].
The trial figures come from the company; WHO's announcement says trials showed it prevents almost all HIV infections among people at risk [6]. Real-world results can differ. AVAC reports that in countries with more than six months of use, most people are returning on time for their second injection, but not necessarily at the more than 90% seen in the trials [2].
There is one serious safety rule. The US label carries a boxed warning about the risk of drug resistance if the injection is used by someone with undiagnosed HIV: people must test HIV-negative before starting and before each injection [5]. WHO has recommended a simplified public health approach using HIV rapid tests to support delivery [6].
Which countries have lenacapavir for PrEP?
Eswatini and Zambia began programme delivery in December 2025, and UNAIDS says 24 countries are expected to have started by the end of 2026 with support from the Global Fund and/or PEPFAR [1]. The UNAIDS list is: Benin, Botswana, the Dominican Republic, Eswatini, Fiji, Georgia, Haiti, Honduras, Indonesia, Kenya, Lesotho, Malawi, Morocco, Mozambique, Nigeria, Papua New Guinea, the Philippines, Rwanda, Thailand, South Africa, Uganda, Ukraine, Zambia and Zimbabwe [1].
AVAC's November 2026 update gives more detail, as an advocacy group's tracking rather than an official count [2]:
- Initial 2026 orders covered 12 early adopters: Eswatini, Kenya, Lesotho, Malawi, Mozambique, Nigeria, the Philippines, South Africa, Uganda, Ukraine, Zambia and Zimbabwe.
- Ten African countries had received supplies, with more than 120,000 people starting LEN between December 2025 and August 2026, almost half in South Africa, which launched only in June.
- The Global Fund and PEPFAR are expanding to 17 more countries from late 2026 into the first half of 2027.
Unitaid, a global health agency, put the number of people who had started at more than 125,000 in 10 African countries in its release of 2 November 2026 [3].
How much does lenacapavir cost?
The generic from Dr. Reddy's is to cost US$40 per person per year in the 120 low- and middle-income countries covered by Gilead's voluntary licence [3][4]. UNAIDS adds that about US$15 to 17 is needed for the oral loading component at the start, and that generic supply is expected from 2027 [1].
The US$40 price comes from a September 2025 agreement between Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI), the Clinton Health Access Initiative (CHAI) and Dr. Reddy's [3][4]. Unitaid says this puts the injection at a price in line with oral PrEP, a key condition for use in poorer countries [3].
The price does not apply everywhere: it covers the 120 low- and middle-income countries in Gilead's licence [3]. AVAC notes that the licences exclude a number of high-burden middle-income countries, especially in Asia and Latin America [2]. The US price of Gilead's brand is not covered here because insurance and assistance programmes change what people pay.
Is generic lenacapavir approved?
Yes, tentatively: on 2 November 2026 Dr. Reddy's announced that the US FDA had granted tentative approval to its long-acting injectable lenacapavir for PrEP, under the FDA's PEPFAR programme [4]. Unitaid explains that tentative approval is the FDA's standard designation for generics while the original product is still under patent, and that it enables procurement by the US government [3]. Dr. Reddy's describes the aim as access in 120 countries outside the US [4].
The approval came 16 months after the FDA approved Gilead's original product in June 2025 [3]. Unitaid says Dr. Reddy's combined the drug's prevention and treatment uses in one application, which allowed a priority review [3].
Next steps are WHO prequalification and national regulatory approvals [3][4]. Dr. Reddy's says first supplies are expected to reach countries before the end of 2026, with broader availability in 2027 [4]. AVAC reports that, as of November 2026, the Global Fund's Expert Review Panel had cleared procurement of Hetero and Dr. Reddy's vials pending full approval, and that lenacapavir has 19 regulatory approvals [2]. AVAC dated the FDA decision to "the end of October", but the company and Unitaid announced it on 2 November and do not state the FDA decision date [2][3][4].
What are the problems with the lenacapavir rollout?
The main problem is supply: AVAC says demand is outpacing the doses in countries, and some programmes are limiting sites and slowing promotion until more supplies are confirmed [2]. UNAIDS also notes that demand has outpaced supply in early-adopter countries [1].
- Volumes: 2026 procurement totalled 1.2 million doses, enough for about 600,000 person-years of protection, AVAC says, against a Global Fund and PEPFAR commitment of three million people over three years [2].
- Advocates' target: AVAC calls for at least three million people in two years (2026-2027) and orders for at least 2.4 million people in 2027 [2]. This is a campaign position, not an agreed plan.
- Systems: UNAIDS urges countries to build on existing PrEP programmes, avoid parallel systems, engage regulators early and monitor adverse events, pregnancy outcomes and drug resistance [1].
- Funding: UNAIDS says regulatory approval and service readiness do not guarantee access; patent status, licensing terms, procurement eligibility and market size also shape access over time [1].
On the positive side, AVAC reports that LEN is the preferred PrEP option when users are given a choice [2].
What happens next with lenacapavir?
2027 is expected to be a transition year, with supplies from both Gilead and generic makers, and generics taking over from 2028, according to AVAC [2]. UNAIDS advises a phased roll-out that starts in a limited number of sites and expands, and says countries should build the generic price into financial planning from 2027 [1].
AVAC also mentions monthly oral alimatravir as a possible new option from 2028, but only "if it is also shown to be safe and effective"; it is not approved [2].
Claims about HIV medicines spread quickly online, including fake "lenacapavir for sale" offers. Genuine PrEP comes through health services and approved programmes. The Pouyam guides AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated and AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers explain how to check medical information that comes from software or chatbots.
This is not medical advice. Anyone interested in PrEP should speak to a health worker or national HIV programme.
| Date | Milestone | Source type |
|---|---|---|
| 18 Jun 2025 | US FDA approves Yeztugo (lenacapavir) for PrEP, people 35 kg or more | Company (Gilead) |
| 14 Jul 2025 | WHO recommends injectable lenacapavir as a PrEP option | WHO |
| Sep 2025 | US$40-a-year generic price agreement (Unitaid, Wits RHI, CHAI, Dr. Reddy's) | Unitaid, company |
| Dec 2025 | Eswatini and Zambia start programme delivery | UNAIDS |
| 2 Nov 2026 | Dr. Reddy's and Unitaid announce FDA tentative approval for the first generic | Unitaid, company |
| 11 Nov 2026 | UNAIDS implementation guide published | UNAIDS |
| End of 2026 | 24 countries expected to have started delivery | UNAIDS |
| 2027 | Generic product availability expected | UNAIDS, company |
Common mistakes
Calling lenacapavir an HIV vaccine.
Fix: It is an antiretroviral medicine used as PrEP; WHO says an HIV vaccine remains elusive [6].
Skipping the HIV test before an injection.
Fix: The US label requires a negative HIV test before starting and before each injection because of the risk of drug resistance [5].
Saying the generic is approved for sale in the US.
Fix: It received tentative approval, a designation that, according to Unitaid, enables procurement by the US government; Dr. Reddy's describes the aim as access in 120 countries outside the US [3][4].
Treating AVAC targets as official plans.
Fix: AVAC is an advocacy group; its three-million-in-two-years goal is a call to action [2].
Frequently asked questions
What is the lenacapavir HIV shot?
A twice-yearly injectable medicine used as PrEP to prevent HIV, given with an oral loading dose; WHO recommended it in July 2025 [1][6].
How effective is lenacapavir for HIV prevention?
In Gilead's Phase 3 PURPOSE trials, at least 99.9% of people on lenacapavir stayed HIV-negative [5].
Which countries have lenacapavir for PrEP?
Eswatini and Zambia started in December 2025; UNAIDS expects 24 countries to have started by the end of 2026 [1].
Glossary
- PrEP
- Pre-exposure prophylaxis: HIV medicine used by people who do not have HIV to reduce the risk of getting it [5].
- Capsid inhibitor
- A drug that targets the protein shell of HIV; Dr. Reddy's describes lenacapavir as a first-in-class capsid inhibitor [4][5].
- Oral loading dose
- Tablets taken at the start of lenacapavir PrEP, before the twice-yearly injections continue [1][5].
- Tentative approval
- An FDA designation for generics while the original is under patent; it allows US government procurement [3].
Sources
- Introducing long-acting injectable lenacapavir as HIV pre-exposure prophylaxis: implementation considerations UNAIDS · 2026-11-11
- Now What with Injectable LEN for PrEP, version 2.0 (advocacy brief) AVAC
- U.S. FDA approves first generic injectable lenacapavir for HIV prevention Unitaid · 2026-11-02
- U.S. FDA grants tentative approval for Dr. Reddy's twice-yearly injectable lenacapavir Dr. Reddy's Laboratories · 2026-11-02
- Yeztugo (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection Gilead Sciences · 2025-06-18
- WHO recommends injectable lenacapavir for HIV prevention World Health Organization · 2025-07-14
Comments
Top comments